13 May 2020 --- Marinova’s Maritech fucoidan, a natural compound derived from seaweed, can reduce flu severity by significantly reducing clinical symptoms and lung damage in a severe influenza A H1N1 model, according to a new mouse study funded by the Australian biotechnology company. The reduction of both symptoms and lung damage in the form of consolidation observed in the study points to the potential for fucoidan to be utilized in nutritional supplements to manage viral infections where lung damage occurs. The company is now screening the in vitro activity of Maritech fucoidan with regard to COVID-19.
